<DOC>
	<DOCNO>NCT00180167</DOCNO>
	<brief_summary>Single Arm-Studies suggest improve remission survival rate Protocol Mitoxantron 10mg/m2 3 day combine AraC 1g/m2 bid day 1+3+5+7 compare conventional DA 7+3 protocol ( 45mg/m2 Daunorubicin ) .</brief_summary>
	<brief_title>Therapy Acute Myeloid Leukemia Patients Over Age 60 : DA Versus Mitoxantrone With Intermittent AraC</brief_title>
	<detailed_description>Randomized comparison two protocol .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Diagnosis AML age &gt; 60 previous Chemo AML inform consent Karnofsky &gt; 70 AML M3 uncontrolled Sepsis uncontrolled HYpertension respiratory failure heartfailure NYHA IV , recent myocardial infarction severe organ dysfunction liver , kidney , HIV infection active Hepatitis B , C</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>elderly</keyword>
</DOC>